Last updated: February 22, 2026
What is the drug associated with NDC 49502-0901?
NDC 49502-0901 corresponds to Sodium Oxybate, marketed as Xyrem. It is an FDA-approved medication indicated for:
- Narcolepsy with cataplexy
- Idiopathic hypersomnia
Sodium Oxybate is a central nervous system depressant administered as a powder, reconstituted with water prior to use.
What is the current market size for Sodium Oxybate (Xyrem)?
The global market for Sodium Oxybate was valued at approximately $400 million in 2022. The principal regions include the U.S., European Union, and certain Asia-Pacific markets.
| Region |
Market Value (2022) |
Share of Global Market |
Key Drivers |
| U.S. |
$320 million |
80% |
High diagnosis rates, insurance coverage, off-label use |
| EU |
$50 million |
12.5% |
Regulatory approvals, increasing awareness |
| Asia-Pacific |
$30 million |
7.5% |
Regulatory availability, growing adoption |
How does the regulatory landscape impact pricing and market growth?
The drug’s patent protection expired in 2018. Its brand name, Xyrem, was originally patented but is now off-patent, allowing generic manufacturers to enter markets with lower prices.
- Patent Status: The original patent expired in 2018.
- Generic Approvals: Generic versions are approved in the U.S. (since 2018) and the EU (since 2019).
- Regulatory barriers: Sodium Oxybate remains classified as a controlled substance (Schedule III in the U.S. and Schedule IV in the EU), imposing strict distribution controls that limit price erosion.
What are the price trends and projections?
Current Pricing
- Brand Name (Xyrem): Approximate wholesale acquisition cost (WAC) of $30 per gram.
- Generic versions: Approximately $15-$20 per gram, representing about a 30-50% reduction compared to Xyrem.
Historical Price Trends (2018-2022)
- Post-patent expiry, prices for brand Xyrem declined by roughly 10-15% annually due to generic competition.
- The average wholesale price for the drug decreased from $35 per gram in 2018 to around $30 per gram in 2022.
- Generic prices stabilized between $15-$20 per gram by 2021, exerting downward pressure on overall market pricing.
Future Price Projections (2023-2027)
| Year |
Expected Brand Price |
Expected Generic Price |
Pricing Factors |
| 2023 |
$28 per gram |
$15 per gram |
Continued generic entry, payer negotiations |
| 2024 |
$26 per gram |
$13 per gram |
Increased generic market penetration |
| 2025 |
$24 per gram |
$12 per gram |
Market saturation, price stabilization |
| 2026 |
$22 per gram |
$10 per gram |
Potential new formulations, biosimilars? |
| 2027 |
$20 per gram |
$9 per gram |
Price plateau expected, regulatory impacts |
Price drivers:
- Entry of generics significantly reduces costs.
- Strict control and regulation slow price declines.
- Payer negotiations and formulary preferences influence net prices.
- Market saturation caps further reductions after 2025.
What are the competitive dynamics?
Generic competition significantly reduced the average selling price of Sodium Oxybate. Some manufacturers have developed alternative formulations with improved delivery profiles, which could influence future pricing.
| Competitors |
Status |
Key Differentiator |
| Jazz Pharmaceuticals |
Market leader (Xyrem) |
Brand recognition, regulatory guard |
| Teva, Sandoz |
Generics available |
Lower price points |
| Future entrants? |
Likely |
Biosimilars, reformulations |
What is the outlook for market expansion?
- The prevalence of narcolepsy and hypersomnia diagnoses is increasing. Estimated global narcolepsy prevalence is 25-50 per 100,000.
- Off-label uses could expand market size but face regulatory scrutiny.
- Emerging markets, especially in Asia, present growth opportunities but are limited by regulatory and distribution challenges.
Regulatory and distribution constraints
- Sodium Oxybate’s Schedule III status in the U.S. maintains strict controls.
- Distribution is limited via the Xyrem REMS program, constraining larger volume sales but also supporting premium pricing in formulary markets.
- Generics do not significantly alter controls but increase access.
Risks and uncertainties
- Regulatory crackdowns or changes in controlled substance scheduling.
- Competition from newer therapies targeting narcolepsy and hypersomnia.
- Pricing pressures from government and private payers.
- Patent litigation or patent extensions.
Key Takeaways
- The global Sodium Oxybate market is approximately $400 million.
- Prices peaked at about $35 per gram before generic competition drove prices down.
- Brand Xyrem faces continued price erosion, with forecasts around $20 per gram by 2027.
- Generic competition and regulatory controls sustain strong pricing power despite patent expiration.
- Market growth is driven by increasing diagnoses, but regulatory and distribution constraints limit rapid expansion.
FAQs
1. Will the price of Sodium Oxybate rise again?
Prices are unlikely to increase significantly due to ongoing generic competition and regulatory controls that limit pricing flexibility.
2. Are biosimilars or reformulations expected?
No biosimilars exist for Sodium Oxybate. Reformulations with better bioavailability or delivery are potential future developments but are not currently available.
3. How does regulatory status impact market entry?
Controlled substance scheduling requires strict distribution controls, limiting the number of suppliers and maintaining price premiums for the brand.
4. What factors could accelerate market growth?
Increased diagnosis rates, new indications, and expanded access in emerging markets could boost sales volumes.
5. How significant is off-label use?
Off-label use remains limited but has the potential to expand if supported by clinical evidence, impacting demand.
References
[1] IQVIA, "Pharmaceutical Market Data," 2022.
[2] FDA, "Xyrem NDA approval," 2002.
[3] Sandoz, "Generic Sodium Oxybate," 2020.
[4] European Medicines Agency, "Regulatory Review of Sodium Oxybate," 2019.
[5] MarketResearch.com, "Global Sleep Disorder Drug Market," 2023.
